Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IntercureINCR 69 EV-to-EBIT is -16.56 as of Sep. 21, 2026. GuruFocus rates INCR with a GF Score™ of 69/100 and a GF Value™ of $5.74 (Fairly Valued). The stock has 5 warning signs investors should review. Among 682 Drug Manufacturers companies, Intercure ranks worse than 146627.42% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Intercure's Enterprise Value for the quarter that ended in Dec. 2025 was $97.04 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Intercure's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $-7.58 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Intercure EV-to-EBIT Related Terms
Intercure EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Intercure's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Intercure's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intercure EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Intercure's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Intercure's EV-to-EBIT falls into.
Intercure's current Enterprise Value is $125.42 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Intercure's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $-7.58 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Intercure (INCR) has a EV-to-EBIT of -16.56 as of Sep. 21, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Intercure and its competitors. According to the industry distribution chart, Intercure ranks #999999 out of 682 companies in the Drug Manufacturers industry.
Is Intercure's EV-to-EBIT too high?
Intercure's current EV-to-EBIT is -16.56. Based on the distribution chart, Intercure ranks #999999 out of 682 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Intercure has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Intercure's EV-to-EBIT compare to CTOR and ZYBT?
According to the Drug Manufacturers industry distribution chart, Intercure ranks #999999 out of 682 companies for EV-to-EBIT. This places Intercure in the lower half of its industry. The industry median EV-to-EBIT is 16.08. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 16.08, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Intercure and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 16.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Intercure's current EV-to-EBIT is -16.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intercure stock overvalued right now?
Based on GuruFocus' analysis, Intercure (INCR) is currently considered Fairly Valued. The stock's GF Value™ is $5.74, compared to a current price of $5.31 — trading 7.5% below its estimated fair value. The current EV-to-EBIT is -16.56. Intercure's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Intercure (INCR), the current EV-to-EBIT is -16.56 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Intercure (INCR) Overvalued in 2026?
Based on GuruFocus' analysis, Intercure stock appears to be undervalued.
The current stock price of $5.31 is trading 7.5% below its estimated GF Value™ of $5.74.
GuruFocus considers Intercure to be Fairly Valued.
Key valuation signals for INCR:
EV-to-EBIT: -16.56
GF Value™: $5.74 vs. price of $5.31 (7.5% below fair value)
No single metric tells the full story. See the INCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.
69GF Score
Get the complete analysis for INCR
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INCR has been successfully added to your 
